BUSINESS

Astellas, Cytokinetics Agree to Develop, Commercialize Skeletal Muscle Activators

June 27, 2013

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Astellas Pharma announced on June 26 that it has formed an agreement with US-based Cytokinetics to collaborate in the research, development, and commercialization of skeletal muscle activators. Astellas and the American biotech firm will codevelop CK-2127107, a fast skeletal troponin…

To read the full story

Astellas, Cytokinetics Expand Collaboration into ALS
July 29, 2016

BUSINESS

Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
UCB, Daiichi Sankyo to Wind Up Japan Partnership for Vimpat
March 3, 2026
Itochu Snaps Up CoreMed to Bolster Japan Entry Support
March 3, 2026
Ono to Transfer Opalmon, Prostandin to Daito by November
March 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…